The White House released a national drug control strategy in May, which calls for consensus public health measures including overdose-reversal medication naloxone, medication-assisted treatment, and test strips used to detect fentanyl or other drug supply adulterants. However, the strategy appears to run counter to several recent Trump administration drug policy actions.
Tensions Between Policy and Practice
The new strategy comes just days after the administration issued new restrictions on using federal dollars to distribute test strips and warned against medication-assisted treatment unless accompanied by other services such as counseling. The document, the first released since the Senate confirmed Sara Carter as director of the White House Office of National Drug Control Policy in January, emphasizes hardline actions including construction of a wall along the Mexican border, deporting drug traffickers, and targeting alleged drug boats in the Caribbean, which experts argue is illegal.
Notably, the strategy makes no mention of syringe exchange programs, seen as an important tool in preventing infectious disease from injection drug use and offering low-barrier connections to medical treatment. Consistent with the administration’s prior crackdowns on supervised consumption and test strips, the strategy does not use the phrase “harm reduction,” a strategy for helping reduce death and disease among people who use drugs without demanding abstinence.
Redirected Resources
The administration has redirected resources “toward transitional housing and treatment-focused programs and removing the enabling environment that allowed open-air drug use to fester in our cities,” according to the strategy document. Among the administration’s most significant drug policy actions to date has been diminishing the Substance Use and Mental Health Administration, for which the White House has never appointed a full-time leader. The administration has canceled billions in funding through the agency and then briefly canceled but soon reinstated roughly $2 billion more issued through it.
The American Society of Addiction Medicine stated that it “appreciates the National Drug Control Strategy’s laudable goal of increasing access to evidence-based treatment for people with substance use disorders” and that “the strategy rightly reinforces addiction as a chronic disease for which evidence-based treatments exist, including medication and psychosocial treatments that save lives and support recovery.”
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.statnews.com/2026/05/06/white-house-drug-control-policy-at-odds-recent-actions/